Upstream Bio (NASDAQ:UPB) Hits New 1-Year Low – What’s Next?

Upstream Bio, Inc. (NASDAQ:UPB) reached a new 52-week low during trading on Saturday . The stock traded as low as $10.24 and last traded at $10.39, with a volume of 206423 shares. The stock had previously closed at $10.77.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on UPB shares. William Blair started coverage on Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. TD Cowen initiated coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, Piper Sandler started coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price target on the stock.

Upstream Bio Trading Down 3.5 %

The stock’s 50-day simple moving average is $17.55.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($6.38). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.83 million. Equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.

Hedge Funds Weigh In On Upstream Bio

An institutional investor recently bought a new position in Upstream Bio stock. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 74,773 shares of the company’s stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned about 0.14% of Upstream Bio at the end of the most recent reporting period.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.